Published in Curr Opin Genet Dev on February 11, 2009
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature (2010) 3.54
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell (2013) 2.92
PML nuclear bodies. Cold Spring Harb Perspect Biol (2010) 2.44
Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell (2010) 2.29
Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev (2010) 1.99
Gamma interferon-dependent transcriptional memory via relocalization of a gene locus to PML nuclear bodies. Mol Cell Biol (2010) 1.07
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. Leukemia (2013) 1.07
Akt-signal integration is involved in the differentiation of embryonal carcinoma cells. PLoS One (2013) 0.97
Role of the promyelocytic leukaemia protein in cell death regulation. Cell Death Dis (2012) 0.90
PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal. Stem Cells (2014) 0.90
Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest (2014) 0.89
Adult Stem Cells and Diseases of Aging. J Clin Med (2014) 0.88
Promyelocytic leukemia inhibits adipogenesis, and loss of promyelocytic leukemia results in fat accumulation in mice. Am J Physiol Endocrinol Metab (2011) 0.88
Glucocorticoid receptors in the retina, Müller glia and the formation of Müller glia-derived progenitors. Development (2014) 0.85
Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells. Dig Dis Sci (2011) 0.84
Distinct germline progenitor subsets defined through Tsc2-mTORC1 signaling. EMBO Rep (2015) 0.82
Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies. Cell Cycle (2014) 0.78
Alteration of protein prenylation promotes spermatogonial differentiation and exhausts spermatogonial stem cells in newborn mice. Sci Rep (2016) 0.75
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase. BMC Cancer (2016) 0.75
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
Applying the principles of stem-cell biology to cancer. Nat Rev Cancer (2003) 8.95
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene (2005) 7.50
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 7.35
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 6.84
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1982) 5.95
Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell (2007) 5.94
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol (2008) 5.90
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 5.79
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol (2004) 5.10
Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A (2007) 4.81
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med (2008) 4.76
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 4.68
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Cancer stem cells: lessons from leukemia. Trends Cell Biol (2005) 3.90
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood (2006) 3.84
Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 3.62
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer (2005) 3.01
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol (2006) 2.57
FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell (2007) 2.50
Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature (2008) 2.47
A QUANTITATIVE ASSAY FOR THE NUMBER OF MURINE LYMPHOMA CELLS CAPABLE OF PROLIFERATION IN VIVO. Nature (1963) 1.96
Regulation of apoptosis by PML and the PML-NBs. Oncogene (2008) 1.67
Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63
Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche. Biochem Biophys Res Commun (2007) 1.45
Portrait of PTEN: messages from mutant mice. Cancer Sci (2008) 1.44
PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol Cell Neurosci (2002) 1.43
Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res (2007) 1.27
Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol (2000) 1.22
Cancer stem cells refined. Nat Immunol (2004) 1.00
Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol (2004) 0.89
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
Does the ribosome translate cancer? Nat Rev Cancer (2003) 6.89
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 5.79
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet (2004) 5.55
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Nucleophosmin and cancer. Nat Rev Cancer (2006) 4.82
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15
Role of nucleophosmin in embryonic development and tumorigenesis. Nature (2005) 4.09
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96
SUMO modification of Huntingtin and Huntington's disease pathology. Science (2004) 3.85
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (2004) 3.75
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell (2011) 3.71
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
A continuum model for tumour suppression. Nature (2011) 3.48
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med (2012) 3.33
The role of PML in tumor suppression. Cell (2002) 3.28
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009) 3.23
The mechanisms of PML-nuclear body formation. Mol Cell (2006) 3.22
PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 3.21
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01
Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol (2009) 2.97
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 2.89
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med (2008) 2.85
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev (2006) 2.76
Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 2.59
Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell (2003) 2.53
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res (2006) 2.50
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 2.45
PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 2.40
Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol (2003) 2.33
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell (2010) 2.29
Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci (2010) 2.17
Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol (2002) 2.15
TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. Proc Natl Acad Sci U S A (2009) 2.13
Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci U S A (2013) 2.13
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med (2007) 2.12
Causality and Chance in the Development of Cancer. N Engl J Med (2015) 2.10
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology (2002) 2.03
Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev (2005) 1.99
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res (2007) 1.94
As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol (2003) 1.94
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome. Mol Cell Biol (2008) 1.93
PTEN level in tumor suppression: how much is too little? Cancer Res (2011) 1.90
PTEN and p53: who will get the upper hand? Cancer Cell (2003) 1.84
SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell (2002) 1.80
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75
ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov (2013) 1.74
Signaling control of mRNA translation in cancer pathogenesis. Oncogene (2004) 1.71
The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity (2002) 1.70
Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene (2003) 1.69
Characterization, cryopreservation, and ablation of spermatogonial stem cells in adult rhesus macaques. Stem Cells (2007) 1.65
GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease. J Exp Med (2004) 1.64
Development of promyelocytic zinc finger and ThPOK-expressing innate gamma delta T cells is controlled by strength of TCR signaling and Id3. J Immunol (2009) 1.64